Mucinous tumours of the ovary
| Autor: | Timothy J. Perren, Jay D Naik, Jenny F. Seligmann |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
medicine.medical_specialty endocrine system diseases Colorectal cancer Ovary Pathology and Forensic Medicine Proto-Oncogene Proteins p21(ras) Breast cancer Drug Therapy Proto-Oncogene Proteins Pancreatic cancer Internal medicine medicine Humans Survival rate Ovarian Neoplasms Taxane business.industry General Medicine medicine.disease Adenocarcinoma Mucinous female genital diseases and pregnancy complications Survival Rate Serous fluid medicine.anatomical_structure Mutation ras Proteins Adenocarcinoma Female business |
| Zdroj: | Journal of Clinical Pathology. 65:580-584 |
| ISSN: | 1472-4146 0021-9746 |
| DOI: | 10.1136/jclinpath-2011-200320 |
| Popis: | Mucinous epithelial ovarian cancers (mEOC) are a relatively rare subset of ovarian cancers. Despite a relatively favourable outcome in early disease, the more frequent advanced presentation is associated with poorer response to platinum/taxane chemotherapies, and poorer survival, compared to serous ovarian cancers. We consider some of the fundamental clinico-pathological and molecular features, and existing clinical trial data regarding mEOC. Underlying molecular differences, between mEOC and serous cancers may contribute to the observed clinical differences, including an increased prevalence of K-RAS mutations in mEOC, more in keeping with gastrointestinal tumours. This observation contributes to the rationale for a trial (“mEOC”) investigating the use of “ovarian” versus “gastrointestinal” style chemotherapy. Looking to potential future approaches, we speculate upon the potential impact of emerging technologies on the future investigation and management of mEOC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|